Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F15%3A00063654" target="_blank" >RIV/65269705:_____/15:00063654 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14740/15:00084906
Výsledek na webu
<a href="http://www.tandfonline.com/doi/full/10.1586/17474086.2015.1079123" target="_blank" >http://www.tandfonline.com/doi/full/10.1586/17474086.2015.1079123</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1586/17474086.2015.1079123" target="_blank" >10.1586/17474086.2015.1079123</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
Popis výsledku v původním jazyce
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient.
Název v anglickém jazyce
Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
Popis výsledku anglicky
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Expert Review of Hematology
ISSN
1747-4086
e-ISSN
—
Svazek periodika
8
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
22
Strana od-do
743-764
Kód UT WoS článku
000365125800002
EID výsledku v databázi Scopus
—